Abstract A process for inhibiting platelet aggregation by the addition of a member selected from the group consisting of a compound of the formula: ##SPC1## Wherein is cyclohexane or phenyl; Y is hydrogen, halogen, --CF 3 , --OH, lower alkyl of 1 to 8 carbon atoms, lower alkoxy of 1 to 8 carbon atoms, --CN, --NH 2 , --SH, or --S-lower alkyl of 1 to 8 carbon atoms; and R is hydrogen, lower alkyl of 1 to 8 carbon atoms, inclusive, or a pharmacologically acceptable cation, to in vivo and in vitro platelet systems. In vitro systems include whole blood as kept in blood banks, whole blood as used in heart-lung machines, and platelet-rich concentrates. In vivo systems include human or animal bodies. The process provides a means for treating hemorrhage due to thrombocytopenia which in turn is caused by irradiation, cancer chemotherapy, or immunosuppressants as well as hemophilia due to congenital defects.
Inventors
👤 Neel C. Sekhar
Bibliographic Details
Application Number—
JurisdictionUS
Data Sourcegoogle_patents
Last Synchronized2026-11-04 21:06
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/185; A61K31/19
Claims Analysis
Total Claims: 4
Claim 1
Independent Claim
89 words
A process for inhibiting platelet aggregation in vitro comprising the addition of a compound of the formula: ##SPC2## wherein is phenyl; Y is hydrogen, halogen, --CF 3 , --OH, lower alkyl of 1 to 8 carbon atoms, lower alkoxy of 1 to 8 carbon atoms, --NH 2 , --SH, or --S--lower alkyl of 1 to 8 carbon atoms; and R is hydrogen, or a pharmacologically acceptable cation, to whole blood or platelet-rich concentrates wherein the amount of the compound added is from about 0.01 to 50 micrograms per milliliter.
Claim 2
Dependent Claim
89 words
A process for inhibiting platelet aggregation in vitro comprising the addition of a compound of the formula: ##SPC2## wherein is phenyl; Y is hydrogen, halogen, --CF 3 , --OH, lower alkyl of 1 to 8 carbon atoms, lower alkoxy of 1 to 8 carbon atoms, --NH 2 , --SH, or --S--lower alkyl of 1 to 8 carbon atoms; and R is hydrogen, or a pharmacologically acceptable cation, to whole blood or platelet-rich concentrates wherein the amount of the compound added is from about 0.01 to 50 micrograms per milliliter.
Claim 3
Dependent Claim
12 words
The process of claim 1 wherein the compound added is 5-phenyl-1-indancarboxylic acid.
Claim 4
Dependent Claim
12 words
The process of claim 1 wherein the compound added is 6-chloro-5-phenyl-1-indancarboxylic acid.